Peripheral artery disease (PAD) is a severe manifestation of atherosclerosis. Patients with PAD are at heightened risk for atherothrombotic complications, including myocardial infarction and stroke (MACE); however, there is also an equal or greater risk of major adverse limb events (MALE), such as acute limb ischemia (ALI) and major amputation. Therefore, there is a need for effective medical therapies to reduce the risk of both MACE and MALE. Recent trials have demonstrated the role of thrombin inhibition in reducing the risk of MACE and MALE in PAD patients. One such medical therapy, vorapaxar, is a potent inhibitor of protease activated receptor-1 which mediates the cellular effects of thrombin. Vorapaxar, used in addition to aspirin, has demonstrated robust reductions in MACE and MALE in PAD patients. In this article, we provide a contemporary review of the current state of PAD and the role of antithrombotic medications in the treatment of PAD, as well as the current clinical data on vorapaxar and strategies to integrate vorapaxar into contemporary medical management of peripheral artery disease.
The trajectory of an individual's recovery after traumatic brain injury (TBI) is heterogeneous, with complete recovery in some cases but persistent disability in others. We hypothesized that changes in structural brain network abnormalities guide the trajectory of an individual's recovery post-injury. Our objective was to characterize the variability in recovery post-TBI by identifying a putative neuroimaging biomarker of traumatic axonal injury (TAI) in individuals with mild TBI. We analyzed 70 T1-weighted and diffusion MRIs longitudinally collected from 35 individuals during the subacute and chronic post-injury periods. Each individual underwent longitudinal blood work to characterize blood protein biomarkers of axonal and glial injury and assessment of post-injury recovery in the subacute and chronic periods. By comparing the MRI data of individual cases with 35 controls, we estimated the longitudinal change in structural brain network abnormalities. We validated this proxy measure of TAI with independent measures of acute intracranial injury estimated from head CT and blood protein biomarkers. Post-injury structural network abnormality was significantly higher than controls in both subacute and chronic periods, associated with an acute CT lesion and subacute blood levels of glial fibrillary acid protein (r=0.5, p=0.008) and neurofilament light (r=0.41, p=0.02). Longitudinal change in abnormality associated with change in functional outcome status (r=-0.51, p=0.003) and post-concussive symptoms (BSI: r=0.46, p=0.03; RPQ:r = 0.46, p=0.02). Brain regions that most closely mapped onto symptom change over time corresponded to structural network hubs or areas susceptible to neurotrauma. Structural network abnormalities might be a biomarker of TAI. Assessing changes in brain network abnormality might enable better patient stratification for monitoring recovery after neurotrauma.
Traumatic brain injury is a global public health problem associated with chronic neurological complications and long-term disability. Biomarkers that map onto the underlying brain pathology driving these complications are urgently needed to identify individuals at risk for poor recovery and to inform design of clinical trials of neuroprotective therapies. Neuroinflammation and neurodegeneration are two endophenotypes associated with increases in brain extracellular water content after trauma. The objective of this study was to describe the relationship between a neuroimaging biomarker of extracellular free water content and the clinical features of patients with traumatic brain injury. We analyzed a cohort of 64 adult patients requiring hospitalization for non-penetrating traumatic brain injury of all severities as well as 32 healthy controls. Patients underwent brain MRI and clinical neuropsychological assessment in the subacute (2-weeks) and chronic (6-months) post-injury period, and controls underwent a single MRI. For each subject, we derived a summary score representing deviations in whole brain white matter (1) extracellular free water volume fraction (VF) and (2) free water-corrected fractional anisotropy (fw-FA). The summary specific anomaly score (SAS) for VF was significantly higher in TBI patients in the subacute and chronic post-injury period relative to controls. SAS for VF significantly correlated with neuropsychological functioning in the subacute, but not chronic post-injury period. These findings indicate abnormalities in whole brain white matter extracellular water fraction in patients with TBI and are an important step toward identifying and validating noninvasive biomarkers that map onto the pathology driving disability after TBI.
Background: Anatomy is critical in risk stratification and therapeutic decision making in coronary disease. The relationship between anatomy and outcomes is not well described in PAD. We sought to develop an angiographic core lab within the VOYAGER-PAD trial. The current report describes the methods of creating this core lab, its study population, and baseline anatomic variables. Methods: Patients undergoing lower-extremity revascularization for symptomatic PAD were randomized in VOYAGER-PAD. The median follow up was 2.25 years. Events were adjudicated by a blinded Clinical Endpoint Committee. Angiograms were collected from study participants; those with available angiograms formed this core lab cohort. Angiograms were scored for anatomic and flow characteristics by trained reviewers blinded to treatment. Ten percent of angiograms were evaluated independently by two reviewers; inter-rater agreement was assessed. Clinical characteristics and the treatment effect of rivaroxaban were compared between the core lab cohort and noncore lab participants. Anatomic data by segment were analyzed. Results: Of 6564 participants randomized in VOYAGER-PAD, catheter-based angiograms from 1666 patients were obtained for this core lab. Anatomic and flow characteristics were collected across 16 anatomic segments by 15 reviewers. Concordance between reviewers for anatomic and flow variables across segments was 90.5% (24,417/26,968). Clinical characteristics were similar between patients in the core lab and those not included. The effect of rivaroxaban on the primary efficacy and safety outcomes was also similar. Conclusions: The VOYAGER-PAD angiographic core lab provides an opportunity to correlate PAD anatomy with independently adjudicated outcomes and provide insights into therapy for PAD. (ClinicalTrials.gov Identifier: NCT02504216)